新文章：研究：伊维菌素在卵巢癌中的应用：伊维菌素与一种他汀类药物的协同作用 - 2023 年英国和伊拉克研究人员论文
癌症新再利用药物组合！
伊维菌素 + 他汀类药物
2023 Jawad 等 - 伊维菌素增强匹伐他汀在卵巢癌细胞中的抗癌活性
亮点：
研究人员此前已证明，匹伐他汀（一种降低胆固醇的他汀类药物）在高剂量下可杀死卵巢癌细胞
他们希望找到一种与匹伐他汀协同作用的药物，以降低匹伐他汀在卵巢癌中发挥疗效所需的剂量
他们在 6 种卵巢癌细胞系中测试了伊维菌素 + 匹伐他汀。
他们将两种药物单独和联合使用于六种不同的实验室培养卵巢癌细胞系（包括 COV-318 细胞）。他们测量了：
药物（伊维菌素、匹伐他汀）减缓或停止癌细胞生长的情况。
联合使用是否导致更多癌细胞死亡（凋亡）。
结果：
低剂量伊维菌素对卵巢癌细胞仅有轻微影响
伊维菌素 + 匹伐他汀具有强烈的协同效应
讨论：
Ricardo 等人的先前工作已显示匹伐他汀、紫杉醇和伊维菌素在卵巢癌中存在协同相互作用
这些作者发现，这些药物协同降低了紫杉醇耐药卵巢癌细胞的存活率。
“我们特别感兴趣的是，他汀类药物是否可作为化疗的替代方案，可能用于已对化疗产生耐药的患者，因此我们在无紫杉醇的情况下探索了匹伐他汀和伊维菌素的组合。”
“在本研究中，我们报告了匹伐他汀和伊维菌素之间的协同作用，这种协同作用可能有助于 Ricardo 评估的三药组合中观察到的协同效应”
在 Fuov-1、Cov-362 和 Cov-318 卵巢癌细胞中观察到协同相互作用。
在后两种细胞中，伊维菌素的多个浓度下均观察到协同作用
结论：
再利用药物是癌症护理的未来。
NEW ARTICLE: RESEARCH: IVERMECTIN in OVARIAN CANCER: Ivermectin synergy with a statin - 2023 Paper by UK and Iraqi researchers
New Repurposed Drug combination for Cancer!
Ivermectin + Statin
2023 Jawad et al - Ivermectin augments the anti-cancer activity of pitavastatin in Ovarian Cancer Cells
HIGHLIGHTS:
Researchers previously showed pitavastatin (a cholesterol lowering statin drug) can kill ovarian cancer cells at high doses
They wanted to identify a drug synergistic with pitavastatin to lower the dose needed for pitavastatin to be effective in Ovarian cancer
They tested IVERMECTIN + PITAVASTATIN in 6 Ovarian Cancer cell lines.
They tested the two drugs, separately and together, on six different lab-grown ovarian cancer cell lines (including COV-318 cells). They measured:
How much the drugs (Ivermectin, Pitavastatin) slowed or stopped cancer cell growth.
Whether the combination caused more cancer cells to die (apoptosis).
RESULTS:
Ivermectin used at lower dose had only a mild effect on Ovarian Cancer cells
Ivermectin + Pitavastatin had a strong synergistic effect
DISCUSSION:
Previous work from Ricardo et al. has shown a synergistic interaction between pitavastatin, paclitaxel, and ivermectin in Ovarian Cancer
These authors found that these drugs synergistically decreased the viability of paclitaxel-resistant Ovarian Cancer cells.
“We are particularly interested in whether statins can be used as an alternative to chemotherapy, possibly in patients who have become resistant to chemotherapy, so we explored the combination of pitavastatin and ivermectin in the absence of paclitaxel.”
“In this study, we report synergy between pitavastatin and ivermectin, and this synergy may contribute to the synergy observed in the triple-drug combination evaluated by Ricardo”
A synergistic interaction was observed in Fuov-1, Cov-362 and Cov-318 Ovarian Cancer cells.
In the latter two cells, synergy was observed at multiple concentrations of Ivermectin
CONCLUSION:
Repurposed drugs are the FUTURE of Cancer Care.
